BernardoHaddock LoboGoulartMD

PubMed

• 1 citations
  Continuation of Third-Generation Tyrosine Kinase Inhibitors in Second-Line Trials for-Mutated Non-Small-Cell Lung Cancer: Regulatory Considerations.
  Bernardo H L Goulart, Erin Larkins, Julia A Beaver, Harpreet Singh> ;Journal of Clinical Oncology. 2023 Aug 10
• 2 citations
  Impact of Diagnostic Delays on Lung Cancer Survival Outcomes: A Population Study of the US SEER-Medicare Database.
  Perrin E Romine, Qin Sun, Catherine Fedorenko, Li Li, Mariel Tang, Keith D Eaton, Bernardo H L Goulart, Renato G Martins> ;JCO Oncology Practice. 2022 Jun 1
• 1 citations
  Effect of Clinical Trial Participation on Costs to Payers in Metastatic Non–Small-Cell Lung Cancer
  Cristina Merkhofer, Shasank Chennupati, Qin Sun, Keith D. Eaton, Renato G. Martins, Scott D. Ramsey, Bernardo H. L. Goulart> ;JCO Oncology Practice. 2021 Aug 10
• 9 citations
  Experiences along the diagnostic pathway for patients with advanced lung cancer in the USA: a qualitative study.
  Morhaf Al Achkar, Monica Zigman Suchsland, Fiona M Walter, Richard D Neal, Bernardo H L Goulart, Matthew Thompson> ;BMJ Open. 2021 Apr 22
• 3 citations
  Impact of Clinical Trial Participation on Survival of Patients with Metastatic Non-Small Cell Lung Cancer.
  Cristina Merkhofer, Keith D. Eaton, Renato G. Martins, Scott D. Ramsey, Bernardo H. L. Goulart> ;Clinical Lung Cancer. 2021 Apr 22
• 7 citations
  Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR+ and ALK+ Positive Non-small-cell Lung Cancer Treated in the Real-World.
  Bernardo H. L. Goulart, Shasank Chennupati, Catherine R. Fedorenko, Scott D. Ramsey> ;Clinical Lung Cancer. 2021 Feb 4
• 9 citations
  Out-of-Pocket Costs for Tyrosine Kinase Inhibitors and Patient Outcomes in EGFR- and ALK-Positive Advanced Non-Small-Cell Lung Cancer.
  Bernardo H. L. Goulart, Joseph M. Unger, Shasank Chennupati, Catherine R. Fedorenko, Scott D. Ramsey> ;JCO Oncology Practice. 2021 Feb 1
• 3 citations
  Complexities of Next-Generation Sequencing in Solid Tumors: Case Studies
  Alexandra O. Sokolova, Brian H. Shirts, Eric Q. Konnick, Ginger J. Tsai, Bernardo H. L. Goulart, Bruce Montgomery, Colin C. Pritchard, Evan Y. Yu, Heather H. Cheng> ;Journal of the National Comprehensive Cancer Network. 2020 Sep 1
• 13 citations
  A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
  Angel Qin, Ramesh Rengan, Sylvia Lee, Rafael Santana-Davila, Bernardo H. L. Goulart, Renato G. Martins, Christina S. Baik, Gregory P. Kalemkerian, Khaled A. Hassan, Br...> ;International Journal of Radiation Oncology, Biology, Physics. 2020 Sep 1
• 101 citations
  A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
  Cristina P. Rodriguez, Qian Vicky Wu, Jenna M. Voutsinas, Jonathan R. Fromm, Xiuyun Jiang, Venu G. Pillarisetty, Sylvia Lee, Rafael Santana-Davila, Bernardo H. L. Goul...> ;Clinical Cancer Research. 2020 Feb 15
• 5 citations
  Intensity modulated radiation therapy following lumpectomy in early-stage breast cancer: Patterns of use and cost consequences among Medicare beneficiaries.
  Lia M. Halasz, Shilpen Patel, Jean A. McDougall, Catherine R. Fedorenko, Qin Sun, Bernardo H. L. Goulart, Joshua A. Roth> ;Plos One. 2019 Sep 30
• 3 citations
  Cross-registry neural domain adaptation to extract mutational test results from pathology reports
  Anthony Rios, Eric B. Durbin, Isaac Hands, Susanne M. Arnold, Darshil Shah, Stephen M. Schwartz, Bernardo H. L. Goulart, Ramakanth Kavuluru> ;Journal of Biomedical Informatics. 2019 Sep 1
• 46 citations
  Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non–Small-Cell Lung Cancer
  Lotte Maria Gertruda Steuten, Bernardo H. L. Goulart, Neal J. Meropol, Daryl Pritchard, Scott D. Ramsey> ;JCO Clinical Cancer Informatics. 2019 Jun 26
• 8 citations
  Validity of Natural Language Processing for Ascertainment of EGFR and ALK Test Results in SEER Cases of Stage IV Non–Small-Cell Lung Cancer
  Bernardo H. L. Goulart, Emily Silgard, Christina S. Baik, Aasthaa Bansal, Qin Sun, Eric B. Durbin, Isaac Hands, Darshil Shah, Susanne M. Arnold, Scott D. Ramsey, Ramak...> ;JCO Clinical Cancer Informatics. 2019 May 6
• 5 citations
  Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of ou...
  Perrin E. Romine, Renato G. Martins, Keith D. Eaton, Douglas E. Wood, Fatemeh Behnia, Bernardo H. L. Goulart, Michael S. Mulligan, Sarah G. Wallace, Elizabeth M. Kell,...> ;BMC Cancer. 2019 Jan 14
• 7 citations
  Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 tr...
  Margaret K. Guerriero, Mary W. Redman, Kelsey Baker, Renato G. Martins, Keith D. Eaton, Laura Qm Chow, Rafael Santana-Davila, Christina S. Baik, Bernardo H. L. Goulart...> ;Cancer. 2018 Jul 1
• 11 citations
  Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies.
  Cristina P. Rodriguez, Renato G. Martins, Christina S. Baik, Laura Qm Chow, Rafael Santana-Davila, Bernardo H. L. Goulart, Sylvia Lee, Keith D. Eaton> ;Head & Neck. 2018 Mar 1
• 1 citations
  Early Steps in the Value of Cancer Care-Many Paths Remain Unexplored.
  Daniel A. Goldstein, Carlo La Vecchia, Bernardo H.L. Goulart> ;The Oncologist. 2018 Apr 1
• 11 citations
  Treatment and outcomes of non-small-cell lung cancer patients with high comorbidity.
  Jorge A. Rios, Rahul Gosain, Bernardo H. L. Goulart, Bin Huang, Margaret N. Oechsli, Jaclyn K. McDowell, Quan Chen, Thomas C. Tucker, Goetz Kloecker> ;Cancer Management and Research. 2018 Jan 24
• 6 citations
  Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma.
  Bruna Pellini Ferreira, Mary W. Redman, Kelsey Baker, Renato G. Martins, Keith D. Eaton, Laura Q.M. Chow, Christina S. Baik, Bernardo H. L. Goulart, Sylvia Lee, Rafael...> ;The Laryngoscope. 2017 Jul 1
• 81 citations
  Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.
  Laura Q.M. Chow, Chihiro Morishima, Keith D. Eaton, Christina S. Baik, Bernardo H. L. Goulart, Leslie N. Anderson, Kristi Manjarrez, Gregory N. Dietsch, James Kyle Bry...> ;Clinical Cancer Research. 2017 May 15
• 7 citations
  Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities.
  Joshua A. Roth, Bernardo H. L. Goulart, Arliene Ravelo, Holli Kolkey, Scott D. Ramsey> ;The Oncologist. 2017 Mar 1
• 7 citations
  Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience.
  Daisuke Araki, Mary W. Redman, Renato G. Martins, Keith D. Eaton, Christina S. Baik, Laura Q.M. Chow, Bernardo H. L. Goulart, Sylvia Lee, Rafael Santana-Davila, Jay J....> ;Head & Neck. 2016 Apr 7
• 9 citations
  Adjuvant Radiotherapy for Stages II and III Resected Thymoma: A Single-institutional Experience.
  Jinchun Yan, Qin Liu, Jessica N. Moseley, Christina S. Baik, Laura Q.M. Chow, Bernardo H. M. Goulart, David Zlotnick, Antoni Papanicolau-Sengos, Ian S. Gallaher, Joy M...> ;American Journal of Clinical Oncology. 2016 Jun 1
• 17 citations
  Value: The Next Frontier in Cancer Care.
  Bernardo H. L. Goulart> ;The Oncologist. 2016 Jun 1
• Join now to see all